|
|
 |
The
REAADER
 |
|
|
The
REAADER is the informational newsletter of Corgenix USA and Corgenix
International. The primary purpose of the REAADER is to keep our customers up to
date on the most recent findings in our area of expertise. Our REAADER
newsletter covers a broad range of topics including articles on autoimmune
disease, antiphospholipid syndrome, thrombosis and hemostasis evaluation.
Join
the REAADER Mailing list today!
Antiphospholipid
Products
Anti-Cardiolipin
(aCL) IgG/IgM Test Kit
Measures
IgG and/or IgM anti-cardiolipin antibody levels for use in the diagnosis of
anti-phospholipid syndrome and the risk assessment of increased blood clotting
(thrombosis) in the general population.
|
Date |
Title |
| March
2007 |
Overview:
5th International Congress on Autoimmunity |
| Oct.
2005 |
Anti-Phospholipid
Testing 101 - Past, Present & Future Part III:
Assays to Test: What, When and Why |
| Aug.
2005 |
Anti-Phospholipid
Testing 101 - Past, Present & Future Part II:
Standardization: What it Means and How it Affects
Results |
| June
2005 |
Anti-Phospholipid
Testing 101 - Past, Present & Future Part
I: The Evolution of aPL Assay Development |
| Feb.
2003 |
New
Multi-Point Calibration Method for Corgenix Anti-Phospholipid
Assays |
| Dec.
2002 |
The
10th International Congress on Antiphospholipid
Antibodies |
| June
2002 |
A
Synopsis of The First Tutzing (Munich)
Antiphospholipid Conference
|
| April
2002 |
The Significance and Increasing Importance
of IgA Antiphospholipid Antibodies |
| Aug. 2001 |
Evaluation of The Relative sensitivity and Accuracy of Four
Antiphospholipid Antibody Assays |
| June 2001 |
The Significance Of Antiphospholipid Antibodies In A Patient
With Angioimmunoblastic Lymphadenopathy (AILD) |
| Apr. 2001 |
The Serologic Evaluation of Thrombosis: Comparative
Performance of Four Antiphospholipid Antibody Assays |
| Feb. 2001 |
Evaluation of Antiphospholipid Antibody recovery of Matched
Serum and Citrated Plasma Samples On Four Antiphospholipid Assays |
| Dec. 2000 |
Practical Application of Suggested Antiphospholipid Testing
Algorithm in aCL Negative, aPS Positive Antiphospholipid Syndrome Patient |
| Oct. 2000 |
The 9th International Symposium On Antiphospholipid
Antibodies |
| Oct.
1999 |
A Practical Algorithm for
the Lab Eval. of APA |
| June 1999 |
Comparative Clinical
Performance of REAADS APA Tests: an Interpretive Tool |
| Apr.
1999 |
A Decade of APA Testing:
Update on Clinical Performance and Interpretive Ranges |
| Feb. 1999 |
Simultaneous
Determination of aCL, aPS and aB2GPI Antibodies:
Correlation with the APS |
| Dec. 1998 |
The 8th International
Symposium on Antiphospholipid Antibodies |
| Apr. 1998 |
Hypercoagulable States and Thrombotic Risk Assessment |
| Feb. 1998 |
APA Testing: A Current Review |
| Dec. 1996 |
Antiphospholipid Antibodies:
Mechanisms of Thrombosis |
| Feb. 1996 |
Antiphospholipid Antibody Testing:
Standardization and Clinical Interpretation of Results |
| Aug. 1995 |
Understanding
Anticardiolipin Antibody Testing |
| Apr.
1995 |
Complexities of aCL Assay Standardization |
| Dec. 1994 |
The Sixth International Symposium on Antiphospholipid
Antibodies |
| Oct.
1992 |
The Fifth International Symposium on Antiphospholipid
Antibodies |
Anti-Cardiolipin
(aCL) IgA Test Kit
Measures
IgA anti-cardiolipin antibody levels for use in the diagnosis of anti-phospholipid syndrome and the risk assessment of increased blood clotting
(thrombosis) in the general population.
|
Date |
Title |
| March
2007 |
Overview:
5th International Congress on Autoimmunity |
| Oct.
2005 |
Anti-Phospholipid
Testing 101 - Past, Present & Future Part III:
Assays to Test: What, When and Why |
| Aug.
2005 |
Anti-Phospholipid
Testing 101 - Past, Present & Future Part II:
Standardization: What it Means and How it Affects
Results |
| June
2005 |
Anti-Phospholipid
Testing 101 - Past, Present & Future Part
I: The Evolution of aPL Assay Development |
| Feb.
2003 |
New
Multi-Point Calibration Method for Corgenix Anti-Phospholipid
Assays |
| Feb.
2003 |
New
Multi-Point Calibration Method for Corgenix Anti-Phospholipid
Assays |
| Dec.
2002 |
The
10th International Congress on Antiphospholipid
Antibodies |
| June
2002 |
A
Synopsis of The First Tutzing (Munich)
Antiphospholipid Conference
|
| April
2002 |
The Significance and Increasing Importance
of IgA Antiphospholipid Antibodies |
| June 2001 |
The Significance Of Antiphospholipid Antibodies In A Patient
With Angioimmunoblastic Lymphadenopathy (AILD) |
| Apr. 2001 |
The Serologic Evaluation of Thrombosis: Comparative
Performance of Four Antiphospholipid Antibody Assays |
| Dec. 2000 |
Practical Application of Suggested Antiphospholipid Testing
Algorithm in aCL Negative, aPS Positive Antiphospholipid Syndrome Patient |
| Oct. 2000 |
The 9th International Symposium On Antiphospholipid
Antibodies |
| Oct.
1999 |
A Practical Algorithm for
the Lab Eval. of APA |
| June 1999 |
Comparative Clinical
Performance of REAADS APA Tests: an Interpretive Tool |
| Apr.
1999 |
A Decade of APA Testing:
Update on Clinical Performance and Interpretive Ranges |
| Feb. 1999 |
Simultaneous
Determination of aCL, aPS and aB2GPI Antibodies:
Correlation with the APS |
| Dec. 1998 |
The 8th International
Symposium on Antiphospholipid Antibodies |
| Apr. 1998 |
Hypercoagulable States and Thrombotic Risk Assessment |
| Feb. 1998 |
APA Testing: A Current Review |
| Dec. 1996 |
Antiphospholipid Antibodies:
Mechanisms of Thrombosis |
| Feb. 1996 |
Antiphospholipid Antibody Testing:
Standardization and Clinical Interpretation of Results |
| Aug. 1995 |
Understanding
Anticardiolipin Antibody Testing |
| Apr.
1995 |
Complexities of aCL Assay Standardization |
| Dec. 1994 |
The Sixth International Symposium on Antiphospholipid
Antibodies |
| Oct.
1992 |
The Fifth International Symposium on Antiphospholipid
Antibodies |
Anti-Phosphatidylserine
(aPS) IgG/IgM Test Kit
Measures
IgG and/or IgM anti-phosphatidylserine antibody levels for use in the diagnosis
of anti-phospholipid syndrome and the risk assessment of increased blood
clotting (thrombosis) in the general population. Phosphatidylserine, a platelet and endothelial cell
membrane lipid, participates in the coagulation cascade making it a more
relevant antigen for use in anti-phospholipid testing.
|
Date |
Title |
| March
2007 |
Overview:
5th International Congress on Autoimmunity |
| Oct.
2005 |
Anti-Phospholipid
Testing 101 - Past, Present & Future Part III:
Assays to Test: What, When and Why |
| Aug.
2005 |
Anti-Phospholipid
Testing 101 - Past, Present & Future Part II:
Standardization: What it Means and How it Affects
Results |
| Feb.
2003 |
New
Multi-Point Calibration Method for Corgenix Anti-Phospholipid
Assays |
| Dec.
2002 |
The
10th International Congress on Antiphospholipid
Antibodies |
| June
2002 |
A
Synopsis of The First Tutzing (Munich)
Antiphospholipid Conference
|
| April
2002 |
The Significance and Increasing Importance
of IgA Antiphospholipid Antibodies |
| Aug. 2001 |
Evaluation of The Relative sensitivity and Accuracy of Four
Antiphospholipid Antibody Assays |
| June 2001 |
The Significance Of Antiphospholipid Antibodies In A Patient
With Angioimmunoblastic Lymphadenopathy (AILD) |
| Apr. 2001 |
The Serologic Evaluation of Thrombosis: Comparative
Performance of Four Antiphospholipid Antibody Assays |
| Feb. 2001 |
Evaluation of Antiphospholipid Antibody recovery of Matched
Serum and Citrated Plasma Samples On Four Antiphospholipid Assays |
| Dec. 2000 |
Practical Application of Suggested Antiphospholipid Testing
Algorithm in aCL Negative, aPS Positive Antiphospholipid Syndrome Patient |
| Oct. 2000 |
The 9th International Symposium On Antiphospholipid
Antibodies |
| Oct.
1999 |
A Practical Algorithm for
the Lab Eval. of APA |
| June 1999 |
Comparative Clinical
Performance of REAADS APA Tests: an Interpretive Tool |
| Apr.
1999 |
A Decade of APA Testing:
Update on Clinical Performance and Interpretive Ranges |
| Feb. 1999 |
Simultaneous
Determination of aCL, aPS and aB2GPI Antibodies:
Correlation with the APS |
| Dec. 1998 |
The 8th
International Symposium on Antiphospholipid Antibodies |
| April 1998 |
Hypercoagulable States
and Thrombotic Risk Assessment |
| Feb. 1998 |
APA Testing: A Current
Review |
| Dec. 1996 |
Antiphospholipid
Antibodies: Mechanisms of
Thrombosis |
| Aug. 1996 |
Cofactor Dependency of
aPS Antibodies Correlates with Thrombosis in SLE Patients |
| June 1996 |
Relative to Cofactor
Dependency, aPS Antibodies are Distinct and more Clinically Relevant than aCL
Antibodies |
| Apr.
1996 |
Laboratory Determination of aPS Antibodies |
| June 1995 |
Determination,
Prevalence, and Clinical Significance of aPS Antibodies |
| Feb. 1995 |
The
Increasing Importance of aPS Antibodies |
Anti-Phosphatidylserine
(aPS) IgA Test Kit
Measures
IgA anti-phosphatidylserine antibody levels for use in the diagnosis
of anti-phospholipid syndrome and the risk assessment of increased blood
clotting (thrombosis) in the general population. Phosphatidylserine, a platelet and endothelial cell
membrane lipid, participates in the coagulation cascade making it a more
relevant antigen for use in anti-phospholipid testing.
|
Date |
Title |
| March
2007 |
Overview:
5th International Congress on Autoimmunity |
| Oct.
2005 |
Anti-Phospholipid
Testing 101 - Past, Present & Future Part III:
Assays to Test: What, When and Why |
| Aug.
2005 |
Anti-Phospholipid
Testing 101 - Past, Present & Future Part II:
Standardization: What it Means and How it Affects
Results |
| Feb.
2003 |
New
Multi-Point Calibration Method for Corgenix Anti-Phospholipid
Assays |
| Dec.
2002 |
The
10th International Congress on Antiphospholipid
Antibodies |
| June
2002 |
A
Synopsis of The First Tutzing (Munich)
Antiphospholipid Conference
|
| April
2002 |
The Significance and Increasing Importance
of IgA Antiphospholipid Antibodies |
| Aug.
2001 |
Evaluation of The Relative sensitivity and Accuracy of Four
Antiphospholipid Antibody Assays |
| June 2001 |
The Significance Of Antiphospholipid Antibodies In A Patient
With Angioimmunoblastic Lymphadenopathy (AILD) |
| Apr. 2001 |
The Serologic Evaluation of Thrombosis: Comparative
Performance of Four Antiphospholipid Antibody Assays |
| Dec. 2000 |
Practical Application of Suggested Antiphospholipid Testing
Algorithm in aCL Negative, aPS Positive Antiphospholipid Syndrome Patient |
| Oct. 2000 |
The 9th International Symposium On Antiphospholipid
Antibodies |
| Apr.
2000 |
The Significance of IgA Anti-Phosphatidylserine
(aPS) Antibodies |
Anti-Beta
2 Glycoprotein I (B2GPI) IgG/IgM/IgA Test Kit
Measures
IgG, IgM, IgA anti-beta 2 glycoprotein I antibody levels for use in the
diagnosis of anti-phospholipid syndrome and the risk assessment of increased
blood clotting (thrombosis) in the general population.
Antibodies recognizing beta 2 glycoprotein I, a natural anticoagulant
which serves as a necessary cofactor for most anti-phospholipid binding, are
reported to be a more specific marker for thrombosis than antibodies detected by
classic antiphospholipid ELISAs (anti-cardiolipin, anti-phosphatidylserine
|
Date |
Title |
| Sept.
2007 |
Antiphospholipid
Antibodies Risk Facts for Coronary Artery Disease |
| March
2007 |
Overview:
5th International Congress on Autoimmunity |
| Oct.
2005 |
Anti-Phospholipid
Testing 101 - Past, Present & Future Part III:
Assays to Test: What, When and Why |
| Aug.
2005 |
Anti-Phospholipid
Testing 101 - Past, Present & Future Part II:
Standardization: What it Means and How it Affects
Results |
| Feb.
2005 |
The Clinical Significance of IgG
Autoantibodies to oxLDL/B2GPI Complex |
| Oct.
2004 |
The Clinical Significance of
Circulating Oxidized Low-Density Lipoprotein
Cholesterol-B2 Glycoprotein 1 (oxLDL-B2GP1)
Complexes |
| Feb.
2004 |
The Emerging Importance of anti-B2
Glycoprotein and anti-Phosphatidylserine
Antibodies in the Laboratory Evaluation of the
Antiphospholipid Syndrome |
| Aug.
2004 |
Autoimmune-Mediated
Atherosclerosis: Autoantibodies Against
oxLDL/ b2GPI
Complexes |
| June
2004 |
Atherosclerosis in Systemic
Autoimmune Diseases and Antiphospholipid
Syndrome: Possible Role in oxLDL/B2GPI
Complexes as Atherogenic Autoantigens |
| Feb.
2004 |
The Emerging Importance of anti-B2
Glycoprotein 1 and anti-Phosphatidylserine
Antibodies in the Laboratory Evaluation of the
Antiphospholipid Syndrome |
| Dec.
2002 |
The
10th International Congress on Antiphospholipid
Antibodies |
| Oct.
2002 |
Standardization of Anti-B2GPI
Antibody ELISAs: Performance of 3 Commercial
Assays on Selected Thrombosis Samples |
| June
2002 |
A
Synopsis of The First Tutzing (Munich)
Antiphospholipid Conference
|
| April
2002 |
The Significance and Increasing Importance
of IgA Antiphospholipid Antibodies |
| Aug. 2001 |
Evaluation of The Relative sensitivity and Accuracy of Four
Antiphospholipid Antibody Assays |
| June 2001 |
The Significance Of Antiphospholipid Antibodies In A Patient
With Angioimmunoblastic Lymphadenopathy (AILD) |
| Apr. 2001 |
The Serologic Evaluation of Thrombosis: Comparative
Performance of Four Antiphospholipid Antibody Assays |
| Feb. 2001 |
Evaluation of Antiphospholipid Antibody recovery of Matched
Serum and Citrated Plasma Samples On Four Antiphospholipid Assays |
| Dec. 2000 |
Practical Application of Suggested Antiphospholipid Testing
Algorithm in aCL Negative, aPS Positive Antiphospholipid Syndrome Patient |
| Oct. 2000 |
The 9th International Symposium On Antiphospholipid
Antibodies |
| Oct.
1999 |
A Practical Algorithm for the Lab
Eval. of APA |
| June 1999 |
Comparative Clinical
Performance of REAADS APA Tests: an Interpretive Tool |
| Apr.
1999 |
A Decade of APA Testing:
Update on Clinical Performance and Interpretive Ranges |
| Feb. 1999 |
Simultaneous
Determination of aCL, aPS and aB2GPI Antibodies:
Correlation with the APS |
| Dec. 1998 |
The 8th
International Symposium on Antiphospholipid Antibodies |
| Aug. 1998 |
Antibodies to B2GPI:
Correlation with Thrombosis in SLE Pts. |
| June 1998 |
Prevalence of aB2GPI
Antibodies in Healthy and Diseased Populations Detected by ELISA |
| April 1998 |
Hypercoagulable States
and Thrombotic Risk Assessment |
| Feb. 1998 |
Anti-Phospholipid Antibody Testing:
A Current Review |
| June 1997 |
Lab Evaluation of the
Antiphospholipid Syndrome: the Significance Of Antibodies to b2-GPI |
| Dec. 1996 |
Antiphospholipid
Antibodies: Mechanisms of
Thrombosis |
| Oct.
1996 |
b2-GPI
and its Role in Anti-Phospholipid Testing |
Anti-Prothrombin
(IgG/ IgM) Antibody Test Kit
|
Date |
Title |
| Oct.
2005 |
Anti-Phospholipid
Testing 101 - Past, Present & Future Part III:
Assays to Test: What, When and Why |
| Aug.
2005 |
Anti-Phospholipid
Testing 101 - Past, Present & Future Part II:
Standardization: What it Means and How it Affects
Results |
| Dec.
2004 |
Highlights
from the 11th International Congress on Antiphospholipid
Antibodies |
| Dec.
2002 |
The
10th International Congress on Antiphospholipid
Antibodies |
| June
2002 |
A
Synopsis of The First Tutzing (Munich)
Antiphospholipid Conference
|
| Aug. 2001 |
Evaluation of The Relative sensitivity and Accuracy of Four
Antiphospholipid Antibody Assays |
| June 2001 |
The Significance Of Antiphospholipid Antibodies In A Patient
With Angioimmunoblastic Lymphadenopathy (AILD) |
| Apr. 2001 |
The Serologic Evaluation of Thrombosis: Comparative
Performance of Four Antiphospholipid Antibody Assays |
| Feb.
2001 |
Evaluation of Antiphospholipid Antibody recovery of Matched
Serum and Citrated Plasma Samples On Four Antiphospholipid Assays |
| Oct. 2000 |
The 9th International Symposium On Antiphospholipid
Antibodies |
| June 2000 |
Antibodies to Cofactors:
Evaluation of anti-Prothrombin Antibodies by ELISA in Lupus Anticoagulant (LA)
Plasma Samples |
| Feb.
2000 |
Antibodies to Cofactors:
Significance of anti-Prothrombin Antibodies in the Antiphospholipid Syndrome |
| Aug. 2000 |
Multicentric Evaluation of anti-Prothrombin Antibodies by ELISA in Lupus Anticoagulant (LA)
Positive Plasma Samples |
Autoimmune Products
Anti-dsDNA Test Kit
An
enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative
determination of IgG/IgM anti-dsDNA antibodies in human serum or plasma.
As
an aid in the diagnosis and management of systemic lupus erythematosus (SLE).
|
Date
|
Title
|
| Oct.
2004 |
CDC and WHO Standardization Now Available in REAADS
anti-dsDNA ELISA |
| Aug.1994 |
Clinical
Significance & Detection of Antibodies to DNA |
ANA
ELISA
Screens
for elevated IgG and IgM anti-nuclear antibody levels (specific for HEp-2
antigens) which are associated with various systemic rheumatic diseases
including systemic lupus erythematosus and lupus variants, scleroderma, mixed
connective tissue disease, Sjogren’s Syndrome, CREST, polymyositis and
rheumatoid arthritis.
|
Date
|
Title
|
| Apr. 1994 |
Overview of the Immune System and Autoimmunity |
| Feb. 1992 |
Clinical
Significance of ANA |
Hemostasis Products
Protein C Antigen Test
Kit
Measures
total and free Protein C concentration used in the diagnosis of congenital or acquired
Protein C deficiency.
|
Date |
Title |
| Aug.
2006 |
The Laboratory Evaluation of Protein
C by ELISA |
| April 1998 |
Hypercoagulable States
and Thrombotic Risk Assessment |
| Dec. 1997 |
Resistance To Activated Protein C (Factory V Leiden),
Antiphospholipid Antibodies and Thrombosis |
| Aug. 1997 |
The
Clinical Significance and Measurement of Protein C by ELISA in the Laboratory
Assessment of Thrombosis |
| Dec. 1995 |
Clinical and Laboratory Significance Of Proteins C & S in Coagulation |
Protein S Antigen Test
Kit
Measures
both total and free Protein S concentration used in the diagnosis of congenital
or acquired Protein S deficiency.
|
Date |
Title |
| Dec.
2007 |
New Role for Protein S and the
Protein S-C4b Binding Protein Complex - a Link
Between Autoimmunity and Thrombosis |
| Apr.
1998 |
Hypercoagulable States
and Thrombotic Risk Assessment |
| Dec. 1997 |
Resistance To Activated Protein C (Factory V Leiden),
Antiphospholipid Antibodies and Thrombosis |
| Oct. 1997 |
Clinical Significances and Laboratory Determination Of
Protein S in The Assessment of Thrombosis |
| Aug. 1997 |
The
Clinical Significance and Measurement of Protein C by ELISA in the Laboratory
Assessment of Thrombosis |
| Dec. 1995 |
Clinical and Laboratory Significance Of Proteins C & S in Coagulation |
Monoclonal Free Protein S Antigen Test
Kit
Measures
only free Protein S concentration used in the diagnosis of cogenital or acquired
free Protein S deficiency.
|
Date |
Title |
| Aug. 1999 |
Direct Determination of Free PS by Monoclonal ELISA in the Evaluation of
Hypercoagulability |
| Apr.
1998 |
Hypercoagulable States and Thrombotic Risk Assessment |
| Dec. 1997 |
Resistance To Activated Protein C (Factory V Leiden),
Antiphospholipid Antibodies and Thrombosis |
| Oct. 1997 |
Clinical Significances and Laboratory Determination Of
Protein S in The Assessment of Thrombosis |
von Willebrand
Factor Antigen Test Kit
Measures
total von Willebrand Factor (vWF) concentration (antigenic) for use in the
diagnosis of Type I (quantitative) von Willebrand disease.
|
Date |
Title |
| Dec.2005 |
Complexity
of the Laboratory Evaluation of von Willebrand
Disease-The Use of Multiple Assay Enhances
Diagnostic Accuracy |
| Apr.
2003 |
von
Willebrand Disease Associated with Menorrhagia |
| Aug.
2002 |
The
Clinical Significance of Elevated Von Willebrand
Factor Levels |
| Feb.
2002 |
Classification
of Type II vWD By Elisa Using Monoclonal
Antibodies To Functional Epitopes of vWF |
| Dec.
1999
|
The Laboratory Evaluation of von Willebrand Disease by ELISA
|
| Dec. 1997 |
Resistance To Activated Protein C (Factory V Leiden),
Antiphospholipid Antibodies and Thrombosis |
| Apr.
1997 |
Clinical
Significance and Laboratory Determination of vWF |
von Willebrand
Factor Activity
Measures
von Willebrand Factor (vWF) activity by employing a monoclonal antibody specific
for the functional epitope of vWF and is used in the diagnosis of Type II
(qualitative) von Willebrand disease.
|
Date
|
Title
|
| Dec.2005 |
Complexity
of the Laboratory Evaluation of von Willebrand
Disease-The Use of Multiple Assay Enhances
Diagnostic Accuracy |
| Feb.
2004 |
The Utility of von Willebrand Factor
Activity and Collagen Binding Assay ELISAs in Type
2 von Willebrand Disease |
| Apr.
2003 |
von
Willebrand Disease Associated with Menorrhagia |
| Aug.
2002 |
The
Clinical Significance of Elevated Von Willebrand
Factor Levels |
| Feb.
2002 |
Classification
of Type II vWD By Elisa Using Monoclonal Antibodies To Functional Epitopes
of vWF |
| Dec.
1999
|
The Laboratory Evaluation of von Willebrand Disease by ELISA
|
Collagen Binding
Measures the binding of von Willebrand Factor (vWF) to collagen. This
assay is currently available in the United States for investigational use only.
| Dec.2005 |
Complexity
of the Laboratory Evaluation of von Willebrand
Disease-The Use of Multiple Assay Enhances
Diagnostic Accuracy |
| Feb.
2004 |
The Utility of von Willebrand Factor
Activity and Collagen Binding Assay ELISAs in Type
2 von Willebrand Disease |
| Dec.
2003 |
Clinical Utility of Collagen Binding
Assay for von Willebrand Factor |
| |
|
Thrombin-Antithrombin
III Complex
Measures thrombin-antithrombin III complex in human plasma. Elevated
plasma levels of TAT have been associated with a wide
variety of thrombotic events.
| Date |
Title |
| Oct.
2003 |
Thrombin-Antithrombin III Complex, a
Marker for Active Thrombosis |
PIFA® Heparin/Platelet Factor 4
Rapid Assay
A
rapid assay used to detect Heparin/PF4 antibodies as a
means to help clinicians identify and treat
patients at risk for Heparin Induced
Thrombocytopenia or thrombosis.
| Date |
Title |
| Feb.
2006 |
A Novel Rapid Testing for the
Assessment of Heparin-Induced
Thrombocytopenia: the PIFA Heparin/PF4 Rapid
Assay |
| Apr.
2005 |
The Diagnosis and Clinical
Significance of Heparin-Induced Thrombocytopenia
(HIT) Type II |
Gastroenterology
Products
Hyaluronic
Acid Test Kit
The
Hyaluronic Acid (HA) quantitative Test kit is an enzyme linked binding protein
assay for the quantitative determination of hyaluronic acid (HA) in human serum
or plasma, The measurement of HA may be used to assess the degree of liver
fibrosis and cirrhosis in chronic liver disease.
|
Date |
Title |
| Dec.
2001 |
Serum Hyaluronic Acid (HA) in Patients
with Chronic Hepatitis C Infection: A Non-Invasive
Marker For Liver Fibrosis and Cirrhosis |
|
Oct.
2001 |
The Clinical Utility of Hyaluronic
Acid (HA) in Rheumatologic and Liver Diseases |
Cardiovascular
Products AtherOx®
Test Kit The
AtherOx™ (oxLDL-B2GPI antigen complex) ELISA Test Kit
detects circulating complex formed by the interaction of
oxidized low-density lipoprotein cholesterol (oxLDL)
with B2 glycoprotein I (B2GPI) in human se | |
